news 30 Oct 2012


​Following months of preparations, Riluzole was launched on the day of patent expiry, October 23rd, by 22 Medis customers in the following markets: France, Spain, Portugal, Austria, Germany, Hungary, Italy, the Netherlands, Sweden and the United Kingdom.

Riluzole is the generic equivalent of Sanofi’s brand Rilutek® and used to treat Amyotrophic lateral sclerosis (ALS) – also referred to as motor neurone disease. Riluzole tablets were developed by the Actavis R&D site in Iceland, and the product is manufactured at the company’s zero-carbon-footprint manufacturing site in Hafnarfjordur.

go up

news and events

go up


worldwide operations and facilities

Created with sketchtool.